Evonik Buys Alkion Biopharma

Germany’s Evonik is strengthening its portfolio of specialty active...
Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. (Lichtmeister/Shutterstock)

Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. Headquartered in Evry, Alkion specializes in developing biotechnological active ingredients for the cosmetics industry. The company has developed methods to cultivate plant biomass under laboratory conditions and can obtain extracts with an exceptionally high yield of complex ingredients.

The entire process takes place without altering the plant genome and results, said Franck Michoux, Alkion’s founder and CEO, in unique, innovative cosmetic actives. With this acquisition, Evonik can now offer customers highly effective customized plant-based ingredients and product concepts that set themselves apart from competitors, said Tammo Boinowitz, head of Evonik’s personal care business.

The transaction is due to be completed this month. Alkion was originally founded as a spin-off from Imperial College London in 2011.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read